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Atrazine (6-chloro-N-ethyl-N´-(1-methyl-
ethyl)-1,3,5-triazine-2,4-diamine) is a triazine 
herbicide widely used in the production of 
corn and other agricultural crops in the United 
States. Atrazine loss from the soil to surface 
water is estimated at 1% per year (Goolsby 
et al. 1991) and may be transported to areas 
as far as 1,000 km from the site of use via 
atmospheric transport and deposition through 
precipitation (Mast et al. 2007; Thurman and 
Cromwell 2000). Several studies have sug-
gested that atrazine is an endocrine disrup-
tor in multiple species, including amphibians 
(Hayes et al. 2002, 2010), fish (Moore and 
Waring 1998), and at high exposure lev-
els in birds (Matsushita 2006) and rodents 
(Eldridge et al. 1999; Friedman 2002; Stoker 
et al. 2000). Some studies have suggested 
that the lower exposure levels that occur in 
the environment may be insufficient to affect 
reproduction in fish, amphibians, or reptiles 
(Solomon et al. 2008). In 2004, the European 
Union banned the use of atrazine because of 
its contamination of water sources (European 
Commission 2004). The International Agency 
for Research on Cancer (IARC) lists atrazine 
as not classifiable as to its carcinogenicity to 
humans (Group 3), although it did determine 
that there is sufficient evidence that it causes 
cancer in rodents (IARC 1999). The U.S. 
Environmental Protection Agency (EPA) is 
currently reviewing its registration decision on 
atrazine (U.S. EPA 2009).
A few epidemiologic studies have evalu-
ated the relationship between atrazine and 
cancer. Case–control studies have shown weak 
associations with non-Hodgkin lymphoma 
(NHL) (De Roos et al. 2003; Hoar Zahm 
et al. 1993; Zahm et al. 1993) and have sug-
gested an increased risk of ovarian (Donna 
et al. 1989) and prostate cancers (MacLennan 
et al. 2002). No associations have been 
observed with leukemia, Hodgkin lymphoma, 
multiple myeloma (Brown et al. 1993), soft-
tissue sarcoma (Hoar et al. 1986), or colon 
cancer (Hoar et al. 1985).
Within the Agricultural Health Study 
(AHS), a large, prospective cohort of licensed 
pesticide applicators and their spouses, a 
previous analysis of cancer and atrazine use 
among pesticide applicators found suggestive 
associations with NHL, multiple myeloma, 
and cancers of the bladder and lung, but 
none were statistically significant (Rusiecki 
et al. 2004). The current study updates the 
previous analysis with an additional 6 years of 
cancer incidence and follow-up data, includ-
ing more than twice as many incident cancer 
cases (n = 3,146), 1,785 of which are addi-
tional cases since the previous publication.
Methods
Cohort description. The AHS is a prospective 
cohort study that includes 57,310 licensed pes-
ticide applicators in Iowa and North Carolina. 
Applicators were recruited and enrolled in the 
study during 1993–1997 when they obtained 
or renewed their licenses to apply restricted 
use pesticides. In North Carolina, only pri-
vate applicators, who are primarily farmers, 
were recruited, whereas in Iowa, both private 
and commercial applicators were included. 
Commercial applicators included persons 
employed by pest control companies or busi-
nesses that use pesticides. Incident cancers 
were ascertained through linkage to state can-
cer registries in Iowa and North Carolina. First 
primary cancers diagnosed from enrollment 
through 31 December 2007 were included in 
this analysis. Annually, cohort members were 
matched to the National Death Index to iden-
tify vital status and to current address records 
of the Internal Revenue Service, motor vehi-
cle registration offices, and pesticide license 
registries of state agricultural departments to 
determine whether they continued to reside in 
Iowa or North Carolina. Follow-up was cen-
sored at the time of cancer incidence, death, 
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Background: Atrazine is a triazine herbicide used widely in the United States. Although it is an 
animal carcinogen, the mechanism in rodents does not appear to operate in humans. Few epidemio-
logic studies have provided evidence for an association.
Methods: The Agricultural Health Study (AHS) is a prospective cohort that includes 57,310 
licensed pesticide applicators. In this report, we extend a previous AHS analysis of cancer risk asso-
ciated with self-reported atrazine use with six additional years of follow-up and more than twice as 
many cancer cases. Using Poisson regression, we calculated relative risk estimates and 95% confi-
dence intervals for lifetime use of atrazine and intensity-weighted lifetime days, which accounts for 
factors that impact exposure.
results: Overall, 36,357 (68%) of applicators reported using atrazine, among whom there were 
3,146 cancer cases. There was no increase among atrazine users in overall cancer risk or at most 
cancer sites in the higher exposure categories compared with the lowest. Based on 29 exposed cases 
of thyroid cancer, there was a statistically significant risk in the second and fourth quartiles of 
intensity-weighted lifetime days. There was a similar pattern for lifetime days, but neither the risk 
estimates nor the trend were statistically significant and for neither metric was the trend monotonic.
conclusions: Overall, there was no consistent evidence of an association between atrazine use and 
any cancer site. There was a suggestion of increased risk of thyroid cancer, but these results are based 
on relatively small numbers and minimal supporting evidence.
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or movement out of the state. Participants 
provided informed consent, and the study pro-
tocol was approved by the institutional review 
boards of the National Institutes of Health, 
the University of Iowa, and other contractors 
in compliance with all applicable requirements 
of the United States.
Exposure assessment. Use of atrazine 
and other factors was assessed through the 
completion of a self-administered question-
naire (available at http://aghealth.nci.nih.gov/ 
questionnaires.html). Participants provided 
information on their use of 50 common pesti-
cides, pesticide application and mixing meth-
ods, repair of pesticide application equipment, 
and use of personal protective equipment. 
Participants also reported on potential risk 
factors such as smoking, alcohol consump-
tion, cancer history of first-degree relatives, 
diet, selected medical conditions, and demo-
graphic information.
Questionnaire data were used to construct 
two measures of atrazine use. The first metric 
was lifetime days of use, calculated by mul-
tiplying the years of reported atrazine use by 
the average number of days per year of use. 
The second exposure metric was intensity-
weighted lifetime days of use, calculated by 
multiplying lifetime days of atrazine use by a 
measure of exposure intensity based on gen-
eral handling practices for pesticides. This 
intensity-weighting algorithm included factors 
that impacted exposure levels, such as whether 
the applicator personally mixed pesticides or 
repaired application equipment, the methods 
of applying pesticides, and the use and type of 
personal protective equipment when handling 
pesticides (Dosemeci et al. 2002). The origi-
nal intensity-weighting algorithm was based 
on questionnaire information, expert review 
of relative exposure levels from published lit-
erature on pesticide exposure, and informa-
tion from the Pesticide Handlers Exposure 
Database (PHED 1992). We recently modi-
fied the weighting factors for the intensity-
weighting algorithm, using data from pesticide 
monitoring studies conducted in subsets of 
AHS participants (Hines et al. 2008; Thomas 
et al. 2010a, 2010b). The results from these 
substudies supported the use of the algorithm 
to assign exposure intensities but indicated 
areas where refinement could be made. The 
updated (v2) algorithm gave more weight 
to the use of chemically resistant gloves for 
reducing exposure, increased the score given 
to broadcast methods of application relative 
to in-furrow application, decreased the score 
given to mixing activities relative to the origi-
nal version of the algorithm, and rescaled the 
range to include integer values.
Data analysis. Of the 57,310 applicators 
in the AHS, we excluded 2,337 who provided 
no or insufficient information on atrazine use 
to calculate lifetime or intensity-weighted 
lifetime days, 1,044 with a cancer diagnosis 
before enrollment, and 267 who had missing 
or zero person-years, leaving 53,662 applica-
tors available for analyses.
We categorized lifetime days of use and 
intensity-weighted lifetime days of use into 
nonexposed and quartiles of exposure among 
users, with categories based on the distribu-
tion of all cancer cases combined. We report 
results for cancer sites with > 20 exposed cases 
and for breast and ovarian cancer, which were 
sites with high a priori interest because of the 
hormonal properties of atrazine. Relative risks 
(RRs) were calculated by Poisson regression 
using SAS (version 9.1; SAS Institute Inc., 
Cary, NC). Subjects contributed person-time 
at risk from year of enrollment (1993–1997) 
through 31 December 2007, date of first can-
cer diagnosis or date moved out of the state, 
whichever was earlier.
Similar to the previous publication, unless 
otherwise noted, models were adjusted for 
race, sex, age (< 50, 50–59, 60–69, ≥ 70 
years), smoking history (never, ≤ 12 pack-
years, > 12 pack-years, regardless of current 
smoking status), alcohol use (yes/no in pre-
ceding 12 months), education (less than high 
school, high school degree, more than high 
school), state of residence (Iowa or North 
Carolina), family history of cancer, applica-
tor type (private or commercial), and ever 
use of other pesticides most highly corre-
lated with atrazine use [dicamba, cyanazine, 
metolachlor, trifluralin, 2,4-D (2,4-dichloro-
phenoxyacetic acid)]. For lung and bladder 
cancer, we additionally adjusted for smoking 
with tertiles of pack-years among former and 
current smokers. For ovarian and breast can-
cer, because of the small number of cases, 
confidence limits were calculated in STATA 
(StataCorp LP, College Station, TX) using 
exact methods. For all cancer sites evaluated, 
associations using both the original and the 
updated versions of the intensity-weighting 
algorithm were similar; therefore, we pres-
ent results based on the updated (version 2) 
algorithm only. All RRs were calculated using 
two different referent groups, those report-
ing no use of atrazine and those in the lowest 
quartile of atrazine use. Applicators in the 
highest categories of atrazine use were more 
similar to those in the lowest quartile of use 
than to nonusers on some characteristics, 
which might suggest the possible presence 
of confounding on unmeasured characteris-
tics. Therefore, analyses using the low-exposed 
group as the referent are reported here. Tests 
for trend used the midpoint value of each 
exposure category treated as a continuous 
variable in Poisson regression models. All tests 
were two-sided and conducted at the 0.05 
alpha level. We performed stratified analyses 
by state and by applicator type to evaluate 
potential differences between the two groups. 
We also stratified on use of chemicals that 
been reported in a case–control study to have 
supra-additive effects with atrazine and NHL 
(carbofuran, diazinon, and alachlor). All data 
used in this analysis are based on AHS data 
release P1REL201005.00. 
Results
Selected demographic characteristics and use 
of correlated pesticides by atrazine use (none, 
lowest quartile, highest three quartiles) are 
reported in Table 1. Pesticide applicators in 
this cohort are overwhelmingly white and 
male. For many characteristics, such as sex, 
state, alcohol use, and use of correlated pes-
ticides, applicators in the highest quartiles 
of use are more similar to applicators in the 
lowest quartile of use than to the nonexposed. 
Private pesticide applicators were more likely 
to have used atrazine than were commercial 
applicators (70% and 50%, respectively). 
However, among commercial applicators who 
reported use of atrazine, the number of days 
per year and total lifetime days of use were 
higher than that among private applicators 
(lifetime days median = 116.0, interquartile 
range, 49.50–457.25 for commercial; life-
time days median = 56.0, interquartile range, 
20.0–178.50 for private applicators).
Overall, there were 4,737 incident cancers 
diagnosed among 53,662 applicators through 
2007, including 1,785 who were diagnosed 
since the previous report on atrazine and can-
cer incidence from the AHS (Rusiecki et al. 
2004). Among the 36,357 atrazine users, 
there were 3,146 incident cancer diagnoses. 
As shown in Table 2, no association for can-
cer overall with either the lifetime days or 
intensity-weighted metric was apparent. For 
most cancer sites, there was little evidence 
for an association between atrazine use and 
incident cancer, including cancers of the pros-
tate and lung, two of the most common sites 
diagnosed in this cohort. In general, results 
for the intensity-weighted and lifetime days of 
use metrics were similar.
Based on 29 exposed cases, there was a sta-
tistically significant association between thy-
roid cancer and atrazine intensity-weighted 
lifetime days of use in the highest quartile of 
use [RR = 4.84; 95% confidence interval (CI), 
1.31–17.93, p-trend = 0.08] (Table 2). For 
lifetime days of use, there was also a suggestion 
of an association in the highest category (RR 
= 2.32; 95% CI, 0.66–8.22, p-trend = 0.61). 
However, neither metric exhibited a mono-
tonic trend. Because obesity has been linked 
with increased risk of thyroid cancer (Kitahara 
et al. 2011), we further adjusted these results 
for body mass index. The RRs for intensity-
weighted lifetime days were 4.30 (95% CI, 
1.21–15.28), 1.09 (95% CI, 0.22–5.43), 
and 4.30 (95% CI, 1.19–15.57) for the sec-
ond, third, and fourth quartiles of exposure, 
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respectively, compared with the lowest quartile 
(p-trend = 0.30). We were not able to stratify 
results by applicator type, because only one 
case of thyroid cancer occurred in commer-
cial applicators and removing this case did 
not change risk estimates (data not shown). 
Twenty-two of the 29 exposed cases occurred 
in Iowa, and the RRs were 3.88 (95% CI, 
1.01–14.90), 0.87 (95% CI, 0.14–5.42), and 
4.50 (95% CI, 1.12–18.15) for the second, 
third, and fourth quartiles. There were no 
cases in North Carolina in the lowest quartile 
of exposure.
Esophageal cancer was significantly ele-
vated in the second category of exposure for 
intensity-weighted lifetime days (RR = 2.83; 
95% CI, 1.03–7.82), but not in the higher 
categories of intensity-weighted lifetime days 
(RR = 2.33; 95% CI, 0.81–6.67 and RR = 
1.78; 95% CI, 0.59–5.30) or for lifetime days 
(Table 2). Similarly, a statistically significant 
increased risk for cancer of the oral cavity in 
the second category of atrazine lifetime use 
compared with the lowest use category was 
observed (RR = 2.09; 95% CI, 1.09–3.99). 
However, the RRs in the higher two quartiles 
were closer to the null (RR = 1.43 and 1.19, 
respectively), and RRs for intensity-weighted 
lifetime days were not significantly elevated. 
RRs for intensity-weighted lifetime days were 
not elevated. For pancreatic cancer (n = 51), 
there were decreased risks in all exposure cat-
egories, which was statistically significant in 
the second exposure category for intensity-
weighted lifetime days (RR = 0.38; 95% CI, 
0.17–0.87, p-trend = 0.18), but no evidence 
of any association with lifetime days of expo-
sure. Based on 24 cases, there were decreased 
risks for laryngeal cancer for both metrics 
of exposure in the second, third, and fourth 
quartiles, although none were statistically sig-
nificant (p-trend = 0.05 and p-trend = 0.09 for 
lifetime and intensity-weighted lifetime days, 
respectively).
Because of a priori interest in hormonally 
related cancers, we also evaluated use of atra-
zine and breast cancer (n = 36) and ovarian 
cancer (n = 9) among female pesticide applica-
tors, although the number of cases was limited. 
We used the nonexposed category as the refer-
ent (n = 1,154) and evaluated only ever use 
of atrazine (n = 312). Results presented are 
adjusted only for age, but results adjusted for 
other factors, including parity, were similar 
(data not shown). There was no association 
between atrazine use and breast cancer based on 
9 exposed and 27 unexposed cases (RR = 1.14; 
95% CI, 0.47–2.50). Assessing risk for those 
above the median level of lifetime days of use 
also provided no evidence of risk. There were 
only four cases of breast cancer among male 
applicators, which precluded us from carrying 
out a separate analysis for breast cancer among 
men. For ovarian cancer, the RR for ever use of 
atrazine was 2.91 (95% CI, 0.56–13.60), based 
on four cases among the women who reported 
atrazine use and five cases among those who 
reported no use. All exposed cases occurred 
among those with less than the median of atra-
zine use among all cancer cases.
Use of atrazine did not appear to be 
associated with any lymphohematopoietic 
malignancy (Table 3). For NHL, RRs were 
near 1.0 for both lifetime days and intensity-
weighted lifetime days. Similarly, null patterns 
were observed for all subtypes. We evalu-
ated potential effect modification by use of 
chemicals previously reported to interact with 
atrazine and NHL (alachlor, carbofuran, and 
diazinon) by conducting analyses stratified by 
Table 1. Selected characteristics of pesticide applicators, by atrazine use category based on enrollment 
questionnaire data, 1993–1997 [n (%)].
Lifetime days of atrazine use
Characteristic
No use of atrazine 
(n = 17,305)
Quartile 1 
(n = 9,523)
Quartiles 2, 3, and 4 
(n = 26,834)
Age (years)
< 50 10,958 (63.3) 5,906 (62.0) 16,526 (61.6)
50–59 3,098 (17.9) 1,897 (19.9) 5,939 (22.1)
60–69 2,292 (13.2) 1,288 (13.5) 3,503 (13.1)
≥ 70 957 (5.5) 432 (4.5) 866 (3.2)
Sex
Male 16,154 (93.3) 9,397 (98.7) 26,648 (99.3)
Female 1,151 (6.7) 126 (1.3) 186 (0.7)
State
Iowa 8,583 (49.6) 6,754 (70.9) 19,780 (73.7)
North Carolina 8,722 (50.4) 2,769 (29.1) 7,054 (26.3)
Smoking status (pack-years)
Never 8,580 (52.9) 5,205 (56.2) 14,408 (55.3)
Former (< 3.75) 1,583 (9.8) 998 (10.8) 2,844 (10.9)
Former (3.75–15 ) 1,571 (9.7) 873 (9.4) 2,440 (9.4)
Former (> 15 ) 1,524 (9.4) 800 (8.6) 2,339 (9.0)
Current (< 11.25) 1,283 (7.9) 475 (5.1) 1,312 (5.0)
Current (11.25–28.5) 1,055 (6.5) 456 (4.9) 1,319 (5.1)
Current (> 28.5) 1,031 (6.4) 450 (4.9) 1,412 (5.4)
Missing 678 266 760
Alcohol use
Never 6,230 (38.3) 2,836 (31.1) 7,387 (28.4)
Ever in last year 10,026 (61.7) 6,287 (68.9) 18,655 (71.6)
Missing 1,049 400 792
Education
< High school 2,143 (13.2) 836 (8.9) 1,896 (7.2)
High school graduate 7,511 (46.2) 4,496 (48.1) 12,976 (49.3)
> High school 7,200 (44.3) 4,011 (42.9) 11,456 (43.5)
Missing 451 180 506
Family history of cancer
No 10,031 (62.8) 5,297 (58.5) 14,774 (57.2)
Yes 5,954 (37.2) 3,750 (41.5) 11,070 (42.8)
Missing 1,320 476 990
Applicator type
Private 14,967 (86.5) 9,173 (96.3) 24,888 (92.7)
Commercial 2,338 (13.5) 350 (3.7) 1,946 (7.3)
Use of dicamba
No 11,908 (76.4) 3,790 (43.5) 9,173 (36.2)
Yes 3,682 (23.6) 4,914 (56.5) 16,160 (63.8)
Missing 1,715 819 1,501
Use of cyanazine
No 13,922 (89.5) 5,064 (58.0) 10,290 (40.4)
Yes 1,625 (10.5) 3,673 (42.0) 15,188 (59.6)
Missing 1,758 786 1,356
Use of metolachlor
No 12,590 (81.1) 4,605 (52.6) 9,573 (37.5)
Yes 2,937 (18.9) 4,143 (47.4) 15,923 (62.5)
Missing 1,778 775 1,338
Use of trifluralin
No 11,369 (73.8) 3,784 (43.0) 8,626 (33.8)
Yes 4,029 (26.2) 5,006 (57.0) 16,910 (66.2)
Missing 1,907 733 1,298
Use of 2,4-D
No 8,165 (47.8) 1,892 (20.0) 3,597 (13.5)
Yes 8,901 (52.2) 7,554 (80.0) 23,056 (86.5)
Missing 239 77 181
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use of these chemicals. We saw no evidence of 
stratum-specific differences (data not shown). 
There was also no association with leukemia 
or multiple myeloma.
Because of the differences in pesticide 
usage patterns between private and com-
mercial applicators and the higher preva-
lence of atrazine usage in Iowa than in North 
Carolina, we also evaluated each cancer site 
stratified by state and by license type (private 
vs. commercial). We observed no meaningful 
differences in the results for any cancer site 
(data not shown).
Discussion
There was no association observed between 
use of atrazine and cancer overall and no evi-
dence for an association with most cancer 
sites. However, there was limited evidence for 
an association with atrazine use and cancer of 
the thyroid and ovaries.
Atrazine is an endocrine-disrupting chemi-
cal. It has been hypothesized that exposure to 
atrazine may alter hormone levels, possibly 
through induction of aromatase, which con-
verts androgens into estrogens (Gammon et al. 
2005). Atrazine causes mammary tumors in 
rats by affecting the hypothalamus, which 
affects the pituitary gland and ultimately dis-
rupts luteinizing hormone cycling, leading 
to increases in endogenous estrogen and pro-
lactin (Gammon et al. 2005). In rats, this 
altered exposure to reproductive hormones 
produces accelerated reproductive aging and 
a hormonal environment that is conducive to 
mammary tumor development. This mecha-
nism does not appear to operate in humans. 
However, the hypothalamic regulation of 
luteinizing hormone and prolactin secretion is 
similar, suggesting that atrazine may influence 
Lifetime days
Intensity-weighted 
lifetime days
Cancer site
No. of 
cases RRa (95% CI)
No. of 
casesb RRa (95% CI)
All
Q1: > 0 to ≤ 20 832 1.00 Reference 786 1.00 Reference
Q2: > 20 to ≤ 56 771 1.03 (0.93–1.13) 785 0.99 (0.90–1.10)
Q3: > 56 to ≤ 178.5 834 1.00 (0.90–1.10) 785 1.03 (0.93–1.14)
Q4: > 178.5 709 1.06 (0.96–1.18) 785 1.01 (0.91–1.11)
p-trend = 0.26 p-trend = 0.90
Prostate
Q1: > 0 to ≤ 20 335 1.00 Reference 316 1.00 Reference
Q2: > 20 to ≤ 56 317 1.05 (0.90–1.22) 331 1.04 (0.89–1.21)
Q3: > 56 to ≤ 178.5 357 1.03 (0.88–1.19) 326 1.06 (0.91–1.24)
Q4: > 178.5 288 1.06 (0.90–1.25) 322 1.04 (0.89–1.22)
p-trend = 0.55 p-trend = 0.81
Lungc
Q1: > 0 to ≤ 20 84 1.00 Reference 65 1.00 Reference
Q2: > 20 to ≤ 56 64 0.89 (0.64–1.24) 69 1.03 (0.73–1.45)
Q3: > 56 to ≤ 178.5 69 0.86 (0.62–1.19) 69 1.03 (0.73–1.46)
Q4: > 178.5 58 0.86 (0.60–1.22) 72 0.93 (0.66–1.32)
p-trend = 0.53 p-trend = 0.56
Colon
Q1: > 0 to ≤ 20 65 1.00 Reference 63 1.00 Reference
Q2: > 20 to ≤ 56 40 0.70 (0.47–1.04) 47 0.75 (0.51–1.09)
Q3: > 56 to ≤ 178.5 67 1.06 (0.75–1.50) 52 0.86 (0.59–1.25)
Q4: > 178.5 64 1.26 (0.88–1.80) 73 1.16 (0.82–1.65)
p-trend = 0.04 p-trend = 0.07
Rectum
Q1: > 0 to ≤ 20 28 1.00 Reference 26 1.00 Reference
Q2: > 20 to ≤ 56 25 0.96 (0.56–1.64) 26 1.02 (0.59–1.76)
Q3: > 56 to ≤ 178.5 33 1.16 (0.69–1.94) 34 1.31 (0.78–2.20)
Q4: > 178.5 27 1.14 (0.66–1.96) 27 1.02 (0.59–1.78)
p-trend = 0.60 p-trend = 0.94
Bladderc
Q1: > 0 to ≤ 20 47 1.00 Reference 41 1.00 Reference
Q2: > 20 to ≤ 56 33 0.79 (0.50–1.24) 34 0.82 (0.52–1.30)
Q3: > 56 to ≤ 178.5 31 0.68 (0.43–1.08) 35 0.88 (0.56–1.39)
Q4: > 178.5 30 0.84 (0.52–1.36) 31 0.75 (0.46–1.21)
p-trend = 0.76 p-trend = 0.34
Oral cavity
Q1: > 0 to ≤ 20 14 1.00 Reference 17 1.00 Reference
Q2: > 20 to ≤ 56 27 2.09 (1.09–3.99) 18 1.10 (0.57–2.15)
Q3: > 56 to ≤ 178.5 20 1.43 (0.72–2.86) 21 1.33 (0.70–2.54)
Q4: > 178.5 13 1.14 (0.53–2.47) 18 1.20 (0.61–2.36)
p-trend = 0.54 p-trend = 0.70
Esophagus
Q1: > 0 to ≤ 20 7 1.00 Reference 5 1.00 Reference
Q2: > 20 to ≤ 56 14 2.11 (0.85–5.25) 15 2.83 (1.03–7.82)
Q3: > 56 to ≤ 178.5 15 1.99 (0.80–4.96) 12 2.33 (0.81–6.67)
Q4: > 178.5 6 0.90 (0.29–2.74) 10 1.78 (0.59–5.30)
p-trend = 0.40 p-trend = 0.74
Lifetime days
Intensity-weighted 
lifetime days
Cancer site
No. of 
cases RRa (95% CI)
No. of 
casesb RRa (95% CI)
Pancreas
Q1: > 0 to ≤ 20 15 1.00 Reference 20 1.00 Reference
Q2: > 20 to ≤ 56 13 0.95 (0.45–2.02) 8 0.38 (0.17–0.87)
Q3: > 56 to ≤ 178.5 10 0.65 (0.29–1.46) 13 0.63 (0.31–1.28)
Q4: > 178.5 13 1.01 (0.46–2.19) 10 0.45 (0.21–0.98)
p-trend = 0.86 p-trend = 0.18
Larynx
Q1: > 0 to ≤ 20 8 1.00 Reference 9 1.00 Reference
Q2: > 20 to ≤ 56 6 0.82 (0.28–2.38) 7 0.76 (0.28–2.04)
Q3: > 56 to ≤ 178.5 8 0.97 (0.35–2.65) 4 0.44 (0.13–1.45)
Q4: > 178.5 2 0.24 (0.05–1.18) 4 0.36 (0.11–1.21)
p-trend = 0.05 p-trend = 0.09
Cutaneous melanoma
Q1: > 0 to ≤ 20 38 1.00 Reference 35 1.00 Reference
Q2: > 20 to ≤ 56 31 0.89 (0.55–1.43) 39 1.15 (0.73–1.82)
Q3: > 56 to ≤ 178.5 29 0.82 (0.50–1.35) 30 0.93 (0.57–1.53)
Q4: > 178.5 34 1.15 (0.71–1.87) 28 0.85 (0.51–1.42)
p-trend = 0.36 p-trend = 0.33
Kidney
Q1: > 0 to ≤ 20 27 1.00 Reference 28 1.00 Reference
Q2: > 20 to ≤ 56 19 0.78 (0.43–1.41) 18 0.65 (0.36–1.17)
Q3: > 56 to ≤ 178.5 29 1.11 (0.65–1.88) 26 0.97 (0.57–1.67)
Q4: > 178.5 24 1.21 (0.69–2.13) 27 1.02 (0.59–1.76)
p-trend = 0.31 p-trend = 0.47
Brain
Q1: > 0 to ≤ 20 9 1.00 Reference 9 1.00 Reference
Q2: > 20 to ≤ 56 9 0.99 (0.39–2.51) 10 1.08 (0.44–2.67)
Q3: > 56 to ≤ 178.5 10 1.01 (0.40–2.52) 11 1.16 (0.48–2.84)
Q4: > 178.5 8 0.97 (0.35–2.70) 6 0.62 (0.21–1.78)
p-trend = 0.92 p-trend = 0.24
Thyroid
Q1: > 0 to ≤ 20 4 1.00 Reference 3 1.00 Reference
Q2: > 20 to ≤ 56 11 2.91 (0.92–9.21) 12 4.55 (1.27–16.24)
Q3: > 56 to ≤ 178.5 7 1.86 (0.53–6.51) 3 1.16 (0.23–5.80)
Q4: > 178.5 7 2.32 (0.66–8.22) 11 4.84 (1.31–17.93)
p-trend = 0.61 p-trend = 0.08
Liver
Q1: > 0 to ≤ 20 6 1.00 Reference 5 1.00 Reference
Q2: > 20 to ≤ 56 8 1.34 (0.46–3.90) 9 1.65 (0.55–4.95)
Q3: > 56 to ≤ 178.5 3 0.47 (0.12–1.94) 3 0.54 (0.13–2.28)
Q4: > 178.5 11 2.13 (0.76–5.99) 11 1.84 (0.62–5.48)
p-trend = 0.09 p-trend = 0.27
Table 2. Solid tumors among 36,357 atrazine users in the AHS, 1993–2007.
Q, quartile.
aControlled for age, state, license type, sex, smoking (never, ≤ 12 pack years, > 12 pack-years), alcohol consumption, education, and use of most highly correlated pesticides.  bNumber of 
cases differ between the two metrics because of missing data for intensity-weighting factors. cAdditionally controlled for smoking as never and tertiles of former and current  smoking. 
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pituitary hormones (Gammon et al. 2005). In 
addition, inhibition of luteinizing hormone 
in male rats has been linked to reduction of 
testosterone (Trentacoste et al. 2001).
We observed a non–statistically signifi-
cant increased risk of ovarian cancer among 
females who ever used atrazine; however, this 
observation is based on only four exposed 
cases. Because of the small number of cases, 
we were able to evaluate only an association 
for ever using atrazine and not any poten-
tial exposure–response relationships, which is 
a limitation of this analysis. We cannot rule 
out chance as an explanation for this find-
ing, even though we explored this association 
based on a priori interest because of the hor-
monal properties of atrazine. Uncontrolled 
confounding could also explain these results. 
We previously reported an excess risk of ovar-
ian cancer incidence and mortality among all 
female pesticide applicators in the AHS com-
pared with the general population of Iowa 
and North Carolina (Alavanja et al. 2005; 
Koutros et al. 2010; Waggoner et al. 2010). 
The absence of an excess for ovarian cancer 
among the approximately 32,000 women 
married to pesticide applicators but who are 
not themselves licensed applicators suggests 
that either pesticides or other occupational 
factors may contribute to the excess among 
female pesticide applicators. There is a paucity 
of epidemiologic literature on ovarian can-
cer and atrazine. Case–control studies in Italy 
and California of ovarian cancer and triazine 
exposure, the chemical group to which atra-
zine belongs, were suggestive of an association, 
but neither was statistically significant (Donna 
et al. 1989; Young et al. 2005). An ecologic 
study showed an inverse association between 
district-level exposure metrics (which included 
public drinking water atrazine levels, acreage of 
corn planted, and sales of atrazine) and ovarian 
cancer (Hopenhayn-Rich et al. 2002).
Compared with nonusers, there was little 
evidence of an increased risk of breast can-
cer among female pesticide applicators who 
reported use of atrazine, based on nine exposed 
cases. Data from other epidemiologic studies 
of breast cancer and atrazine are limited. An 
earlier study within the AHS that included 
wives of pesticide applicators reported no asso-
ciation between breast cancer and atrazine 
use, whether use was classified by personal 
use or use by the husband (Engel et al. 2005). 
Ecologic studies have generally not suggested 
such associations (Hopenhayn-Rich et al. 
2002; Mills and Yang 2006), although one 
study in England observed a spatial association 
between breast cancer incidence rates and the 
application of atrazine in one county, but not 
another (Muir et al. 2004). The IARC classifi-
cation for atrazine is Group 3 (not classifiable), 
but the Working Group determined that there 
was sufficient evidence for carcinogenicity in 
animals because of the association with mam-
mary tumors. However, they determined that 
the atrazine-associated mammary tumors 
observed in rats involved a hormonally medi-
ated mechanism not relevant for humans 
(IARC 1999).
Prostate cancer is a site hypothesized to 
be potentially associated with atrazine because 
of its hormonal etiology. We saw no evidence 
of an association with atrazine use and pros-
tate cancer in this study, which is consistent 
with earlier results from the AHS (Alavanja 
et al. 2003; Rusiecki et al. 2004). In a study 
of pesticide manufacturing workers, there was 
an increased risk of prostate cancer, but this 
population had a very high rate of prostate 
cancer screening and 9 of the 11 cases were 
diagnosed at an early stage (MacLennan et al. 
2002), suggesting that detection bias might be 
partially responsible for the observed results.
We found some evidence for a positive 
association between atrazine use and thyroid 
cancer in this analysis. The epidemiologic 
evidence on pesticides and thyroid cancer is 
scarce. A report from Yugoslavia suggested 
an association with agricultural chemicals 
(Sokic et al. 1994), but no specific pesticides 
were implicated. A cohort of female farm 
Table 3. Lymphohematopoietic malignancies among 36,357 atrazine users in the AHS, 1993–2007.
Lifetime days Intensity-weighted lifetime days
No. of cases RRa (95% CI) No. of casesb RRa (95% CI)
Lymphohematopoietic malignancies
Q1: > 0 to ≤ 20 81 1.00 Reference 81 1.00 Reference
Q2: > 20 to ≤ 56 84 1.12 (0.82–1.52) 84 1.04 (0.76–1.41)
Q3: > 56 to ≤ 178.5 82 0.97 (0.71–1.33) 78 0.98 (0.71–1.34)
Q4: > 178.5 64 0.94 (0.67–1.32) 66 0.83 (0.59–1.16)
p-trend = 0.49 p-trend = 0.17
Leukemia
Q1: > 0 to ≤ 20 23 1.00 Reference 27 1.00 Reference
Q2: > 20 to ≤ 56 31 1.41 (0.82–2.43) 26 0.96 (0.56–1.64)
Q3: > 56 to ≤ 178.5 24 0.97 (0.54–1.73) 24 0.91 (0.52–1.58)
Q4: > 178.5 19 0.95 (0.51–1.79) 19 0.72 (0.39–1.31)
p-trend = 0.46 p-trend = 0.24
NHL
Q1: > 0 to ≤ 20 41 1.00 Reference 38 1.00 Reference
Q2: > 20 to ≤ 56 41 1.10 (0.71–1.70) 45 1.20 (0.78–1.86)
Q3: > 56 to ≤ 178.5 38 0.92 (0.59–1.45) 34 0.93 (0.58–1.48)
Q4: > 178.5 32 0.96 (0.60–1.55) 34 0.93 (0.58–1.50)
p-trend = 0.73 p-trend = 0.48
Mature B-cell lymphoma
Q1: > 0 to ≤ 20 36 1.00 Reference 34 1.00 Reference
Q2: > 20 to ≤ 56 34 1.04 (0.65–1.66) 38 1.12 (0.71–1.79)
Q3: > 56 to ≤ 178.5 31 0.85 (0.52–1.38) 25 0.75 (0.45–1.27)
Q4: > 178.5 28 0.94 (0.57–1.57) 31 0.93 (0.57–1.54)
p-trend = 0.79 p-trend = 0.65
Diffuse large B-cell lymphoma
Q1: > 0 to ≤ 20 20 1.00 Reference 15 1.00 Reference
Q2: > 20 to ≤ 56 14 0.80 (0.40–1.59) 18 1.23 (0.62–2.45)
Q3: > 56 to ≤ 178.5 14 0.73 (0.36–1.47) 11 0.78 (0.35–1.71)
Q4: > 178.5 11 0.73 (0.34–1.57) 15 1.09 (0.52–2.27)
p-trend = 0.52 p-trend = 0.96
Follicular lymphoma
Q1: > 0 to ≤ 20 10 1.00 Reference 10 1.00 Reference
Q2: > 20 to ≤ 56 8 0.85 (0.33–2.17) 10 0.99 (0.41–2.38)
Q3: > 56 to ≤ 178.5 6 0.60 (0.22–1.70) 8 0.80 (0.31–2.05)
Q4: > 178.5 8 0.99 (0.38–2.59) 4 0.39 (0.12–1.28)
p-trend = 0.85 p-trend = 0.07
CLL/SLL/MCL
Q1: > 0 to ≤ 20 5 1.00 Reference 6 1.00 Reference
Q2: > 20 to ≤ 56 6 1.23 (0.37–4.03) 6 0.96 (0.31–3.00)
Q3: > 56 to ≤ 178.5 11 1.87 (0.64–5.47) 4 0.66 (0.18–2.37)
Q4: > 178.5 4 0.77 (0.20–3.00) 9 1.44 (0.49–4.23)
p-trend = 0.47 p-trend = 0.33
Multiple myeloma
Q1: > 0 to ≤ 20 14 1.00 Reference 13 1.00 Reference
Q2: > 20 to ≤ 56 9 0.71 (0.31–1.64) 10 0.71 (0.31–1.63)
Q3: > 56 to ≤ 178.5 13 0.83 (0.38–1.79) 14 0.98 (0.45–2.10)
Q4: > 178.5 13 1.04 (0.47–2.29) 12 0.79 (0.35–1.76)
p-trend = 0.45 p-trend = 0.87
Abbreviations: CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; MCL, mantle cell lymphoma; Q, quartile.
aControlled for age, state, license type, sex, smoking (never, ≤ 12 pack years, > 12 pack-years), alcohol consumption, 
education and use of most highly correlated pesticides. bNumber of cases differ between the two metrics because of 
missing data for intensity-weighting factors. 
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residents in New York indicated a nonsig-
nificant increased standardized incidence ratio 
for thyroid cancer, but without evaluation of 
specific exposures (Wang et al. 2002). The 
previous report from the AHS on cancer inci-
dence and atrazine did not include thyroid 
cancer, because there were < 20 exposed cases, 
the cutoff for presenting results in the ear-
lier paper (Rusiecki et al. 2004); with this 
update, there were 29 cases exposed to atra-
zine. Thyroid cancer is more common among 
women than men; in this study of primarily 
male applicators, there was only one female 
case among 312 atrazine users compared 
with 28 among the 36,045 male applicators 
who applied atrazine. Hyperthyroidism has 
been linked to thyroid cancer in some stud-
ies; however, in a study among spouses of 
applicators in the AHS who applied pesti-
cides, there was no association between use 
of atrazine and this condition (Goldner et al. 
2010). Endocrine-disrupting substances can 
disrupt hormonal synthesis or metabolism 
and may impact the thyroid function in a 
variety of ways (Diamanti-Kandarakis et al. 
2009). However, studies based on bioassays 
specific for atrazine have been generally null 
(Hasegawa et al. 1993), and studies in rodents 
have shown limited effects of atrazine on the 
thyroid (Laws et al. 2000; Son et al. 2003). 
We found a significantly elevated risk for the 
highest versus lowest category of intensity-
weighted atrazine use, but the findings were 
based on a relatively small number of exposed 
cases, and the trend was not monotonic. We 
know of no other reports that have investi-
gated atrazine and thyroid cancer, and this 
association needs further evaluation.
There is some epidemiologic evidence 
for an association between atrazine exposure 
and NHL. Three early case–control studies 
focused on triazine herbicides and showed 
non–statistically significant increased NHL 
risk (Cantor et al. 1992; Hoar et al. 1986; 
Zahm et al. 1993). NHL was more common 
among those who used atrazine compared 
with those who had never worked on a farm, 
based on a pooled analysis of these studies 
(Hoar Zahm et al. 1993); further analysis of 
these pooled data included evidence of supra-
additive effects when atrazine was considered 
in conjunction with other pesticides, namely, 
carbofuran, diazinon, and alachlor (De Roos 
et al. 2003). We saw no such evidence in 
this analysis. In the previous analysis of atra-
zine within the AHS, there was a nonsignifi-
cant excess reported with NHL based on 68 
exposed cases (Rusiecki et al. 2004). Here, we 
observed 152 exposed cases and no evidence 
of association. Other studies of atrazine and 
NHL include a mortality study of pesticide 
manufacturing workers that showed a non–
statistically significant excess of NHL based 
on four deaths (MacLennan et al. 2003). 
Schroeder et al. (2001) evaluated associations 
with agricultural exposures by t(14;18) sub-
types and reported that atrazine was associated 
with NHL among those cases with the trans-
location, but not among those without. The 
translocation was most common in follicular 
(46%), diffuse B cell (39%), other (66%), and 
unclassified (52%) subtypes. In our study, we 
did not have tumor tissue to evaluate such an 
association but were able to look at histologic 
subtypes based on cancer registry records and 
saw no association for any subtype.
We found no association with multiple 
myeloma with either lifetime days of use or 
intensity-weighted lifetime days of use. In 
the previous AHS analysis of atrazine, there 
was a suggestion of an association based on 
23 exposed cases (Rusiecki et al. 2004). Our 
analysis includes an additional 26 exposed 
cases for a total of 49. The only other study 
specifically evaluating multiple myeloma 
showed little evidence for such an association 
(Brown et al. 1993).
A previous analysis of atrazine use in the 
AHS also suggested non–statistically signifi-
cant associations with cancers of the blad-
der and lung (Rusiecki et al. 2004). In this 
update, with more than twice as many cases 
for these sites, we observed no evidence of 
association. To our knowledge, no other stud-
ies support an association at these sites.
Strengths of this study include the collec-
tion of information on atrazine use before the 
diagnosis of cancer, the relatively large num-
ber of exposed cases, and the ability to control 
for potential confounding by use of other 
agricultural chemicals. Although this is a large 
cohort study, there are still few female appli-
cators, limiting the power to evaluate female-
specific cancers such as breast and ovarian 
cancer, which have been hypothesized to be 
associated with atrazine. Additionally, we used 
self-reported information on the use of atra-
zine, the methods of application, and the use 
of personal protective equipment. Although 
this is a limitation, the reliability of the data 
on use of pesticides within this cohort is 
comparable with or more reliable than other 
self-reported data such as diet and medical 
conditions (Blair et al. 2002), and pesticide 
applicators in the AHS report the duration 
and time of first use of specific chemicals con-
sistent with the time that the chemicals first 
became available (Hoppin et al. 2002).
Conclusion
In summary, there was no strong or consis-
tent evidence of an association between atrazine 
and any cancer. There was a non–statistically 
significant increased risk of ovarian cancer 
among female applicators who reported ever 
using atrazine compared with those who did 
not; however, this observation was based on 
a small number of cases among atrazine users 
(n = 4). We found an elevated risk of thyroid 
cancer for the highest versus lowest category of 
intensity-weighted atrazine use, but the trend 
was not monotonic and not statistically signifi-
cant when lifetime days of use was used as the 
exposure metric. An association between atra-
zine and thyroid cancer has not been previously 
reported, to our knowledge. In contrast, we saw 
little evidence for an association between atra-
zine use and other cancers previously reported 
in the literature, such as NHL and leukemia, or 
with cancers of the breast or prostate, for which 
atrazine has been hypothesized to be a risk fac-
tor because of its hormonal properties.
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